Lung Cancer Initiative

Lung Cancer Initiative
at Johnson & Johnson

Lung cancer is the leading cause of cancer deaths globally, and it is often detected too late, with more than half of cases metastasizing by the time they are first diagnosed¹… but there is hope.

With patients at the heart of everything we do, The Lung Cancer Initiative (LCI) at Johnson & Johnson was formed in 2018 to unleash the full potential of lung cancer science to help change the trajectory of this complex disease.

As an R&D engine, the LCI takes a multidisciplinary approach in bringing together the unparalleled expertise, technology, scale and reach across Johnson & Johnson within its Pharmaceutical, Medical Device and Consumer Health sectors, and works with collaborators worldwide to advance innovations that aim to create more effective and personalized treatments for lung cancer with the goal to improve patient outcomes.

Leadership

The LCI leadership team is a small, but diverse entrepreneurial team of global experts in clinical, pharmaceutical, engineering, surgical and early detection sciences dedicated to preventing, intercepting and curing lung cancer.

Avi Spira, M.D., MSc Global Head, LCI
Silvia Chen, Ph.D., MBA Head of China, LCI and WWDA
Hannah McEwen, Ph.D. Head of Engineering Sciences, LCI
Michael Morrissey, Ph.D. Global Head, Early Detection & Data Science, LCI and WWDA
Tina Soares Vice President, LCI & WWDA Scientific & Clinical Operations
Chris Stevenson, Ph.D. Head of Pharmaceutical Sciences, LCI
Philippe Szapary, M.D., MSCE Head of Clinical Development, LCI